Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jun 22;11(13):3590.
doi: 10.3390/jcm11133590.

Laparoscopic versus Open Surgery for Gastric Cancer in Western Countries: A Systematic Review and Meta-Analysis of Short- and Long-Term Outcomes

Giovanni Maria Garbarino  1 , Giovanni Guglielmo Laracca  1 , Alessio Lucarini  1 , Gianmarco Piccolino  1 , Paolo Mercantini  1 , Alessandro Costa  2 , Giuseppe Tonini  3 , Giulia Canali  1 , Edoardo Maria Muttillo  1 , Gianluca Costa  4
Affiliations
Review

Laparoscopic versus Open Surgery for Gastric Cancer in Western Countries: A Systematic Review and Meta-Analysis of Short- and Long-Term Outcomes

Giovanni Maria Garbarino et al. J Clin Med. .

Abstract

Background. The advantages of a laparoscopic approach for the treatment of gastric cancer have already been demonstrated in Eastern Countries. This review and meta-analysis aims to merge all the western studies comparing laparoscopic (LG) versus open gastrectomies (OG) to provide pooled results and higher levels of evidence. Methods. A systematic literature search was performed in MEDLINE(PubMed), Embase, WebOfScience and Scopus for studies comparing laparoscopic versus open gastrectomy in western centers from 1980 to 2021. Results. After screening 355 articles, 34 articles with a total of 24,098 patients undergoing LG (5445) or OG (18,653) in western centers were included. Compared to open gastrectomy, laparoscopic gastrectomy has a significantly longer operation time (WMD = 47.46 min; 95% CI = 31.83−63.09; p < 0.001), lower blood loss (WMD = −129.32 mL; 95% CI = −188.11 to −70.53; p < 0.0001), lower analgesic requirement (WMD = −1.824 days; 95% CI = −2.314 to −1.334; p < 0.0001), faster time to first oral intake (WMD = −1.501 days; 95% CI = −2.571 to −0.431; p = 0.0060), shorter hospital stay (WMD = −2.335; 95% CI = −3.061 to −1.609; p < 0.0001), lower mortality (logOR = −0.261; 95% the −0.446 to −0.076; p = 0.0056) and a better 3-year overall survival (logHR 0.245; 95% CI = 0.016−0.474; p = 0.0360). A slight significant difference in favor of laparoscopic gastrectomy was noted for the incidence of postoperative complications (logOR = −0.202; 95% CI = −0.403 to −0.000 the = 0.0499). No statistical difference was noted based on the number of harvested lymph nodes, the rate of major postoperative complication and 5-year overall survival. Conclusions. In Western centers, laparoscopic gastrectomy has better short-term and equivalent long-term outcomes compared with the open approach, but more high-quality studies on long-term outcomes are required.

Keywords: West; Western; gastric cancer; laparoscopic gastrectomy; laparoscopic surgery; laparoscopy; open gastrectomy.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest. Giovanni Maria Garbarino, Giovanni Guglielmo Laracca, Alessio Lucarini, Gianmarco Piccolino, Paolo Mercantini, Alessandro Costa, Giuseppe Tonini, Giulia Canali, Edoardo Maria Muttillo and Gianluca Costa, have no conflicts of interest or financial ties to disclose.

Figures

Figure 1
Figure 1
PRISMA flowchart.
Figure 2
Figure 2
Forest plots of (a) Operative Time; (b) Blood Loss; (c) Lymph Node Yield.
Figure 2
Figure 2
Forest plots of (a) Operative Time; (b) Blood Loss; (c) Lymph Node Yield.
Figure 2
Figure 2
Forest plots of (a) Operative Time; (b) Blood Loss; (c) Lymph Node Yield.
Figure 3
Figure 3
Funnel plots of (a) Operative time; (b) Blood Loss; (c) Lymph Node Yield; (d) Analgesic Requirement; (e) Time to First Flatus; (f) Time to First Oral Intake; (g) Overall Morbidity; (h) Major Complications; (i) Length of Stay; (j) Mortality; (k) 3-year Overall Survival; (l) 5-year Overall Survival.
Figure 4
Figure 4
Forest plots of (a) Analgesic Requirement; (b) Time to First Flatus; (c) Time to First Oral Intake; (d) Overall Morbidity; (e) Major Complications; (f) Length of Stay; (g) Mortality.
Figure 4
Figure 4
Forest plots of (a) Analgesic Requirement; (b) Time to First Flatus; (c) Time to First Oral Intake; (d) Overall Morbidity; (e) Major Complications; (f) Length of Stay; (g) Mortality.
Figure 4
Figure 4
Forest plots of (a) Analgesic Requirement; (b) Time to First Flatus; (c) Time to First Oral Intake; (d) Overall Morbidity; (e) Major Complications; (f) Length of Stay; (g) Mortality.
Figure 4
Figure 4
Forest plots of (a) Analgesic Requirement; (b) Time to First Flatus; (c) Time to First Oral Intake; (d) Overall Morbidity; (e) Major Complications; (f) Length of Stay; (g) Mortality.
Figure 4
Figure 4
Forest plots of (a) Analgesic Requirement; (b) Time to First Flatus; (c) Time to First Oral Intake; (d) Overall Morbidity; (e) Major Complications; (f) Length of Stay; (g) Mortality.
Figure 4
Figure 4
Forest plots of (a) Analgesic Requirement; (b) Time to First Flatus; (c) Time to First Oral Intake; (d) Overall Morbidity; (e) Major Complications; (f) Length of Stay; (g) Mortality.
Figure 4
Figure 4
Forest plots of (a) Analgesic Requirement; (b) Time to First Flatus; (c) Time to First Oral Intake; (d) Overall Morbidity; (e) Major Complications; (f) Length of Stay; (g) Mortality.
Figure 5
Figure 5
Forest plots of (a) 3-year Overall Survival; (b) 5-year Overall Survival.
Figure 5
Figure 5
Forest plots of (a) 3-year Overall Survival; (b) 5-year Overall Survival.
See this image and copyright information in PMC

References

    1. Esposito G., Dilaghi E., Cazzato M., Pilozzi E., Conti L., Carabotti M., di Giulio E., Annibale B., Lahner E. Endoscopic surveillance at 3 years after diagnosis, according to European guidelines, seems safe in patients with atrophic gastritis in a low-risk region. Dig. Liver Dis. 2020;53:467–473. doi: 10.1016/j.dld.2020.10.038. - DOI - PubMed
    1. Vannella L., Lahner E., Annibale B. Risk for gastric neoplasias in patients with chronic atrophic gastritis: A critical reappraisal. World J. Gastroenterol. 2012;18:1279–1285. doi: 10.3748/wjg.v18.i12.1279. - DOI - PMC - PubMed
    1. Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018;68:394–424. doi: 10.3322/caac.21492. - DOI - PubMed
    1. Ferlay J., Steliarova-Foucher E., Lortet-Tieulent J., Rosso S., Coebergh J.W.W., Comber H., Forman D., Bray F. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012. Eur. J. Cancer. 2013;49:1374–1403. doi: 10.1016/j.ejca.2012.12.027. - DOI - PubMed
    1. Smyth E.C., Verheij M., Allum W., Cunningham D., Cervantes A., Arnold D. Gastric cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2016;27:38–49. doi: 10.1093/annonc/mdw350. - DOI - PubMed

LinkOut - more resources